Russian and foreign experience of evaluating adherence to long-term therapy in patients with rheumatic arthritis: review of literature


DOI: https://dx.doi.org/10.18565/therapy.2019.2.95-103

Bakirov B.A., Zaripova G.R., Akbuldina K.R., Bogdanova Yu.A., Kudlai D.A.

1) Department of hospital therapy No. 2 of Bashkir State medical University of the Ministry of Healthcare of Russia; 2) Department of pharmacology with a course of clinical pharmacology of Bashkir State medical University of the Ministry of Healthcare of Russia; 3) Clinic of Bashkir State medical University of the Ministry of Healthcare of Russia; 4) Institute of immunology State scientific Center of FMBA of Russia
The article presents the results of Russian and foreign studies to assess adherence to therapy in patients with rheumatoid arthritis (RA) , the analysis of the main factors affecting adherence to the basic therapy of RA, in conjunction with the main clinical characteristics of the disease , the psychological status of the patient and the mode of drug therapy.
Keywords: adverse reaction, genetic engineering drugs, drug survival, methods for assessing adherence, adherence to therapy, rheumatoid arthritis
Read entire article

Literature


  1. Кувшинова Н.Ю. Проблема приверженности терапии в различных областях медицины. Известия Самарского научного центра Российской академии наук. 2015; 5(3): 1014–19.

  2. Национальные рекомендации Российского научного медицинского общества терапевтов по количественной оценке приверженности к лечению. М., 2017. 24 с.

  3. Vrijens B., De Geest S., Hughes D.A. A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol. 2012; 73(5): 691–705.

  4. Costedoat-Chalumeau N., Amoura Z., Hulot J.S. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 2007; 66(6): 821–24.

  5. Hess L.M., Raebel M.A., Conner D.A., Malone D.C. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann. Pharmacother. 2006; 40 (7–8): 1280–88.

  6. De Klerk E. Measurement of patient compliance on drug therapy: an overview. In: Advances in Behavioral Medicine Assessment. Vingerhoets A (Ed.). Harwood Academic Publishers. London, UK, 2001:215–44.

  7. Рябинцева Л.Ф., Солодовников А.Г., Лесняк О.М. Изучение приверженности лечению больных хроническими заболеваниями на модели ревматоидного артрита, ее детерминанты и влияние на исходы заболевания. Уральский медицинский журнал. 2009; 2: 32–38.

  8. Marengo M.F., Suarez-Almazor M.E. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? International Journal of Clinical Rheumatology. 2015; 10(5): 1–13.

  9. Bliddal H., Eriksen S.A., Christensen R. Adherence to methotrexate in rheumatoid arthritis: a Danish nationwide cohort study. Arthritis. 2015; 915142. https://doi.org/10.1155/2015/915142

  10. Unk J.A., Brasington R. Efficacy study of multimedia rheumatoid arthritis patient education program. J. Am. Assoc.Nurse Pract. 2014; 26(7):370–77.

  11. Zwikker H.E., van den Ende C.H., van Lankveld W.G. Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: a randomized controlled trial. Patient Educ. Couns. 2014; 94(3): 356–61.

  12. Hill J., Bird H., Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann. Rheum. Dis. 2001; 60(9): 869–75.

  13. Brus H.L.M., van de Laar M.A., Taal E., Rasker J.J., Wiegman O. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann. Rheumat. Dis. 1998; 57: 146–51.

  14. Каратеев Д.Е. Факторы, определяющие длительный успех терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Современная ревматология. 2015; 3: 54–60.

  15. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., Dijkmans B.A., Aarden L., Wolbink G.J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305(14): 1460–68.

  16. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2007; 66: 921–26.

  17. Насонов Е.Л. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научно-практическая ревматология. 2016; (54)5: 557–71.

  18. Thomas S.S., Borazan N., Barroso N. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015; 29(4): 241–58.

  19. Karlsson J.A., Kristensen L.E., Kapetanovic M.C., Gülfe A., Saxne T., Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008; 47(4): 507–13.

  20. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P., Silman A.J. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis & rheumatism. 2007; 56(1): 13–20. DOI 10.1002/art.22331

  21. Katchamart W., Johnson S., Lin H.J., Phumethum V., Salliot C., Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care & Research. 2010; 62(8): 1128–43.

  22. Duran J., Bockorny M., Dalasl D. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systemic review. Ann Rheum Dis. 2016; 75: 1595–98.

  23. Caporali R., Sarzi-Puttini P., Atzeni F., Gorla R., Filippini M., Marchesoni A., Favalli E.G., Bobbio-Pallavicini F., Montecucco C. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev. 2010; 9(6): 465–69.

  24. Elaine M. Dennison, Jon Packham, Kimme Hyrich. The BSRBR-RA at 15 years. Providing real-world insight into the effectiveness and safety of biologic therapies. Rheumatology. 2016; 55(12): 2093–95.

  25. Машкунова О.В., Мынжасарова Ф.А., Турарова Э.Е., Аханова А.З., Алибекова А.А., Омарова М.Б., Талипхан А.Б. Оценка приверженности пациентов с ревматоидным артритом лечению базисными противовоспалительными препаратами. Медицина (Алматы). 2018; 33(189): 65–66.

  26. Vermeer M., Kuper H.H., Bernelot Moens H.J., Hoekstra M., Posthumus M.D., van Rссiel P.L., van de Laar M.A. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Research and Therapy. 2012; 14(6): 254.

  27. Салихов И.Г., Яхин К.К., Ахунова Р.Р. Феномен «стероидной фобии» у больных ревматоидным артритом. Consilium medicum. 2010; 9: 20–23.

  28. Абрамкин А.А. Влияние коморбидных психических расстройств на эффективность терапии у больных ревматоидным артритом. Научно-практическая ревматология. 2016; 3(54): 339–345

  29. Лисицына Т.А., Вельтищев Д.Ю., Насонов Е.Л. Стрессовые факторы и депрессивные расстройства при ревматических заболеваниях. Научно-практическая ревматология. 2013; 51(2): 98–103.

  30. Кремлева О.В. Проблемы нонкомплайентности в соматической клинике: тактика преодоления [Электронный ресурс]. Медицинская психология в России: электронный научный журнал. 2013; 4(21). URL: http://medpsy.ru

  31. Hider S.L., Tanveer W., Brownfield A. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology. 2009; 48(9): 1152–54.

  32. Mattey D.L., Dawes P.T., Hassell A.B. Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. J Rheumatol. 2010; 37(10): 2021–24.

  33. Smolen J.S., Landewґe R., Breedveld F.C. «EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs». Annals of the Rheumatic Diseases. 2010; 69(6): 964–75.

  34. Abbott R., Whear R., Nikolaou V. et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and metaanalysis of the effect on depression and anxiety. J Psychosom Res. 2015 Sep; 79(3): 175–84.

  35. Raison C.L., Rutherford R.E., Woolwine B.J. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013; 70: 31–41.

  36. Uguz F., Akman C., Kucuksarac S., Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci. 2009; 63: 50–55.

  37. Van Hoogmoed D., Fransen J., Bleijenberg G., van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology. 2010; 49: 1294–302.

  38. Wolf F., Michaud K. Fatigue, rheumatoid arthritis and anti-tumor necrosis factor therapy: an investigation in 24831 patients. J Rheumatol. 2004; 31: 2115–20.

  39. Chauffier K., Salliot C., Berenbaum F., Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford). 2012; 51: 60–68.

  40. Schwartzman S., Morgan G.J. Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Research & Therapy. 2004; 6(2): 19–23.

  41. Stoner K.L., Harder H., Fallowfield L.J., Jenkins V.A. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient. 2014 Jul 12. [Epub ahead of print].

  42. Fraenkel L., Bogardus S.T., Concato J., Felson D.T., Wittink D.R. Patient preferences for treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2004; 63(11): 1372–78.

  43. Bergsten U., Bergman S., Fridlund B., Arvidsson B. «Delivering knowledge and advice»: Healthcare providers’ experiences of their interaction with patients’ management of rheumatoid arthritis. International Journal of Qualitative Studies on Health and Well-being. 2011; 6(4): 10.

  44. Henning B., Eriksen S.A., Christensen R., Lorenzen T., Hansen M.S., Ostergaard M., Dreyer L., Luta G., Vestergaard P. Adherence to methotrexate in rheumatoid arthritis: a Danish nationwide cohort study. Arthritis. Volume 2015, Article ID 915142, 7 pages. Hindawi Publishing Corporation http://dx.doi.org/10.1155/2015/915142

  45. Christian A. Waimann, Maria F. Marengo, Sofia de Achaval, Vanessa L. Cox, Araceli Garcia-Gonzalez, John D. Reveille, Marsha N. Richardson, and Maria E. Suarez-Almazor. Electronic Monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis consequences of low adherence. Arthritis & Rheumatism. 2013; 65(6): 1421–29.

  46. Onecia Benjamin, Sarah L. Lappin. Disease Modifying Anti-Rheumatic Drugs (DMARD). StatPearls Publishing LLC. June 2, 2018. Bookshelf ID:NBK507863PMID:29939640.https://www.ncbi.nlm.nih.gov/books/NBK507863

  47. Garcia-Gonzalez A., Richardson M., Garcia Popa-Lisseanu M., Cox V., Kallen M.A., Janssen N., Ng B., Marcus D.M., Reveille J.D., Suarez-Almazor M.E. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008; 27(7): 883–89.

  48. Luciana Resende Prudente, Juliana de Souza Diniz,Tatyana Xavier Almeida Matteucci Ferreira, Dione Marçal Lima, Nílzio Antônio Silva, Guylherme Saraiva,Erika Aparecida Silveira, Nathalie de Lourdes Souza Dewulf, Rita Goreti Amaral. Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Preference and Adherence. 2016; 10: 863–70.

  49. Vik S.A., Maxwell C.J., Hogan D.B. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann. Pharmacother. 2004; 38: 303–12.

  50. Roth H.P., Caron H.S. Accuracy of doctors ‘estimates and patients’ statements on adherence to a drug regimen. Clin. Pharmacol. Ther. 1978; 23: 361–70.

  51. Hill J. Adherence with drug therapy in the rheumatic diseases part two: measuring and improving adherence. Musculoskeletal Care. 2005; 3(3): 143–56.

  52. Matsuyama J.R., Mason B.J., Jue S.G. Pharmacists’ interventions using an electronic medication-event monitoring device’s adherence data versus pill counts. Ann Pharmacother. 1993; 27:851–55.

  53. Bart J.F. van den Bemt, Hanneke E. Zwikker, Cornelia H.M. van den Ende. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev. Clin. Immunol. 2012; 8(4): 337–51.

  54. Kumar K., Gordon C., Toescu V. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of south Asian and White British origin. Rheumatology (Oxford). 2008; 47(5): 690–97.

  55. Garcia-Gonzalez A., Gonzalez-Lopez L., Gamez-Nava J.I., Rodriguez-Arreola B.E., Cox V., Suarez-Almazor M.E. Doctor–patient interactions in Mexican patients with rheumatic disease. J. Clin. Rheumatol. 2009; 15(3): 120–23.

  56. Horne R., Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 1999; 47: 555–67.

  57. Чичасова Н.В. Возможности достижения максимального эффекта при контролируемом лечении ревматоидного артрита в реальной практике. Лечащий врач. 2015; 7. Медицинский научно-практический портал. https://www.lvrach.ru/2015/07/15436257/

  58. Каратеев Д.Е. Как вести больного ревматоидным артритом после достижения ремиссии? Современная ревматология. 2016; 1: 41–47.


About the Autors

Bulat A. Bakirov, MD, professor, head of the Department of hospital therapy №2 of FSBEI of HE «Bashkir State medical University» of the Ministry of Healthcare of Russia. Address: 450075, Ufa, 3 Blücher St. Tel./Fax: +7 (347) 235-32-23. E-mail: bakirovb@gmail.com
Guzel R. Zaripova, PhD., associate professor of the Department of pharmacology with a course of clinical pharmacology, «Bashkir State medical University» FSBEI of HE of the Ministry of Healthcare of Russia, doctor - clinical pharmacologist of the University clinic. Address: 450083, 2 Shafieva St. Tel.: +79191551334. E-mail: vgr1983@mail.ru
Yuliya A. Bogdanova, PhD, associate professor of the Department of pharmacology with a course of clinical pharmacology, «Bashkir State medical University» FSBEI of HE of the Ministry of Healthcare of Russia. Address: 450008, Ufa, 96/98 Pushkina St. Tel.: +7 (917) 491-33-41. E-mail: juladoctor@mail.ru
Kristina R. Akbuldina, doctor – resident physician of the Department of hospital therapy No. 2 of «Bashkir State medical University» FSBEI of HE of the Ministry of Healthcare of Russia. Address: 450075, Ufa, 3 Blücher St. Tel.: +7 (917) 048-63-16. E-mail: kristina.akbuldina@mail.ru
Dmitry A. Kudlai, MD, professor, leading researcher of the laboratory of personalized medicine and molecular immunology No. 71 of the Federal State Budgetary Institution «Institute of immunology Federal research institution» of FMBA of Russia. Address: 115522, Moscow, 24 Kashirskoye shosse St. Tel.: +7 (985) 761-02-37. Email: D624254@gmail.com


Similar Articles

Back to Content

Бионика Медиа